Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
At a glance
What is this study about?
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.
Who may be eligible?
Age 18 Years to 99 Years · Sex: ALL
Locations (605)
- University of Alabama at BirminghamBirmingham, United States· Recruiting
- SEC Clinical ResearchDothan, United States· Recruiting
- Eastern Shore Research InstituteFairhope, United States· Recruiting
- Heart Center Research LLCHuntsville, United States· Recruiting
- HonorHealthPhoenix, United States· Recruiting
- Medical Advancement Centers of ArizonaPhoenix, United States· Recruiting
- Pima Heart and Vascular Clinical ResearchTucson, United States· Recruiting
- Yuma Clinical TrialsYuma, United States· Recruiting
- Arkansas CardiologyLittle Rock, United States· Recruiting
- National Heart InstituteBeverly Hills, United States· Recruiting
- Valley Clinical Trials, LLC dba Flourish ResearchCovina, United States· Recruiting
- National Institute of Clinical ResearchHuntington Beach, United States· Recruiting
+593 more sites — see the official record for the full list.
How to find out more
Amgen Call Center
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.